India’s Sun Pharmaceutical Industries strengthens its immuno-oncology capabilities with acquisition of U.S.-based Checkpoint Therapeutics.
India’s Sun Pharmaceutical Industries strengthens its immuno-oncology capabilities with acquisition of U.S.-based Checkpoint Therapeutics.
The biopharma sector sees soaring merger and acquisition activity in March 2025, with major deals advancing innovation in …
Partnerships harnessing artificial intelligence are revolutionizing drug discovery, reducing timelines and improving candidate success rates.
Asia-Pacific biopharma conferences in early 2025 are forging strategic partnerships, launching research initiatives, and accelerating drug development.
Record venture investment is driving new biotech companies in Australia to accelerate research, clinical development, and global partnerships.
Landmark clinical results suggest preventative therapy could delay or halt Alzheimer’s onset in high-risk individuals, reshaping the outlook …
Atalanta Therapeutics raises $97 million in Series B funding to accelerate RNA interference therapies into Phase 1 trials, …
Despite a cautious capital environment, North American biotech companies secured nearly $2 billion in funding in January 2025, with …
A three-year collaboration between Vertex and Orna Therapeutics brings cutting-edge lipid nanoparticle delivery into the spotlight, aiming to …
Shanghai-based Excalipoint secures rights to two preclinical T-cell engagers from Lepu Biopharma, aiming to fast-track development for solid …
Already a subscriber? Log in